Detailed Narrative
Strong Q3 FY26 Performance Driven by Organic Growth
Entero Healthcare Solutions reported a robust Q3 FY26, with revenue growing 26% year-on-year and 9% quarter-on-quarter to INR1,707 crores. The company's organic growth stood at an impressive 17.1% year-on-year, significantly outpacing the industry's 12% growth and marking the highest organic growth for this financial year. This strong performance led to a 29% year-on-year increase in gross profit to INR173 crores, with gross margins improving by 30 basis points to 10.1%.
EBITDA and Profitability Expansion
The company's EBITDA for Q3 FY26 reached INR68 crores, reflecting a 36% year-on-year growth, and EBITDA margins improved by 30 basis points to 4%. Despite a one-time📎 exceptional impact of INR6.1 crores on PAT due to a new labor code, adjusted PAT grew 36% over last year to INR40 crores, with an adjusted PAT margin of 2.3%. Reported PAT stood at INR34 crores, a 15% year-on-year increase, with a 2% reported PAT margin.
Strategic MedTech Segment Expansion and Margin Accretion
Entero completed key acquisitions in the MedTech segment, including Anand Medilink, Ace Cardiopathy, Bioaide Technologies, and Anand Chemiceutics. These acquisitions are expected to boost the MedTech segment's annualized revenue to over INR1,000 crores post-integration, representing approximately 15% of the total business. Management anticipates a positive impact of 70 to 90 basis points on overall gross margins and 50 to 75 basis points on overall EBITDA margins on a pro forma basis after the integration of these MedTech businesses.
Improved Working Capital and Cash Flow Generation
The company demonstrated significant improvements in working capital management, with like-to-like Net Working Capital (NWC) days improving to 61 days in Q3 FY26 from 66 days in Q1. This focus on efficiency contributed to a positive Operating Cash Flow (OCF) of INR49 crores in the quarter. Management expressed confidence in achieving the full-year OCF target of INR100 crores, driven by continued EBITDA margin expansion and working capital optimization.
Future Capital Allocation and Growth Strategy
Management indicated a strategic shift towards consolidating recent acquisitions and optimizing operations for the next few quarters, rather than pursuing new 'meaningful acquisitions.' While some debt movement is possible, the company is not planning any new equity capital raises. The focus will be on improving margins and cash flows, with new acquisitions potentially being considered in FY28 after the current integration phase. The company also confirmed that FY27 performance is expected to be 'far better than FY26' due to the full-year impact of acquisitions made in H2 FY26.
Robust Operational Moat and Market Reach
Entero highlighted its strong operational moat, serving over 97,600 retail pharmacies and more than 3,000 hospitals across 505 districts in India, supported by 131 strategically located warehouses. The company sources over 89,200 SKUs from more than 3,100 healthcare manufacturers. This extensive network and value proposition, including 2-3 deliveries per day and 24/7 warehouse operations, enable it to grow faster than the industry and consolidate buying for retailers.